Checked Jun 15, 2026
GLP-1 pill vs. shot: what the Wegovy oral launch actually changes about cost and convenience
FDA-approved oral semaglutide (the Wegovy pill, launched 2026) gives patients a genuine new choice. We compare it against injectable Wegovy, compounded semaglutide, and injectable tirzepatide on cost, dosing convenience, efficacy evidence, and availability, using verified cash prices from each program's own pricing page.
For three years, the GLP-1 choice was binary: injectable or nothing. The 2026 FDA approval of the Wegovy pill (oral semaglutide for weight management) changed that. It is a real, FDA-approved tablet, not a compounded troche, not Rybelsus. It is cheaper at maintenance than the injectable Wegovy and costs more than compounded injectable semaglutide. Whether it belongs in your plan depends on three numbers: what you are paying now, whether you inject weekly, and whether you have insurance covering one format but not the other.
- The Wegovy pill ($299/mo at maintenance) is cheaper than the Wegovy injection ($349-$399/mo) at the same NovoCare cash price point.
- Compounded injectable semaglutide is still cheaper than the pill at $178-$249/mo from the main telehealth programs, but it is not FDA-approved and carries supply risk.
- Rybelsus is not the Wegovy pill. Rybelsus is an oral semaglutide for type 2 diabetes, costs ~$998/mo cash, and is not indicated for weight loss. They share the molecule; everything else differs.
- Tirzepatide (Zepbound) remains the highest-efficacy injectable option in published trials, with ~20% average weight loss at 15mg/week, versus ~15% for injectable semaglutide.
- The Wegovy pill's $149/mo starter price (4mg) rises to $199 after August 31, 2026. Budget the $299 maintenance-dose price for sustained treatment planning.
What the 2026 oral approval actually changed
The story people missed: the Wegovy pill is not Novo Nordisk's first oral semaglutide. That was Rybelsus (2019), a 3mg-14mg tablet for type 2 diabetes that was occasionally prescribed off-label for weight management but costs ~$998/month cash without insurance. The Wegovy pill is a distinct product, approved specifically for chronic weight management, with a dedicated NovoCare cash program pricing it at $149/month for starter doses and $299/month for maintenance.
That $299 maintenance price matters because the branded injectable path through NovoCare runs $349-$399/month after the intro period. For a cash-pay patient on branded semaglutide, switching from the shot to the pill saves $50-$100 per month at the same molecule, the same manufacturer, and the same regulatory approval standard. The tradeoff is a daily pill that must be taken on an empty stomach versus a once-weekly injection.
Compounded injectable semaglutide still undercuts both at $178/month from Mochi Health. But that comparison involves a different regulatory chain: 503A-compounded, not FDA-approved, with supply continuity tied to pharmacy compliance and ongoing litigation around tirzepatide.
Every format compared
Prices verified against each program's published pricing as of Jun 15, 2026. Cash prices only. Insurance copays excluded.
| Format | Regulatory status | Cash price | Dosing schedule | Availability |
|---|---|---|---|---|
| Compounded semaglutide (injectable) | Not FDA-approved (503A pharmacy) | From $178/mo Mochi Health, all-in, flat at every dose | Weekly self-injection | Most US telehealth programs; supply risk under litigation |
| Wegovy injection (branded) | FDA-approved (Novo Nordisk) | $349-$399/mo NovoCare cash, after intro offer; intro $199/mo ended June 30, 2026 | Weekly self-injection (0.25mg-2.4mg) | Broad; insurance coverage growing after CMS ruling |
| Wegovy pill (oral, branded) | FDA-approved (Novo Nordisk, 2026) | $149/mo starter / $299/mo maintenance NovoCare: $149 for 1.5mg/4mg starter doses; $299 for 9mg/25mg maintenance | Daily oral tablet, empty stomach | Hims, Ro, WeightWatchers Clinic, Knownwell, NovoCare direct |
| Ozempic (injectable semaglutide, T2D) | FDA-approved for T2D (Novo Nordisk) | ~$998/mo cash without insurance Retail pharmacy; NovoCare savings card requires T2D Rx | Weekly self-injection (0.25mg-2mg) | Requires T2D diagnosis for on-label prescribing |
| Rybelsus (oral semaglutide, T2D) | FDA-approved for T2D (Novo Nordisk, 2019) | ~$998/mo cash without insurance Cash retail; covered with T2D diagnosis | Daily oral tablet, empty stomach | Requires T2D diagnosis for on-label prescribing |
| Mounjaro / Zepbound injection (tirzepatide) | FDA-approved: Zepbound (weight loss), Mounjaro (T2D) | Zepbound: $299-$449/mo (vials), $449/mo (KwikPen) LillyDirect cash; Mounjaro ~$998-$1,036/mo without T2D insurance | Weekly self-injection (2.5mg-15mg) | Zepbound via telehealth for weight loss; Mounjaro requires T2D Rx |
| Compounded tirzepatide (injectable) | Not FDA-approved (503A pharmacy) | From $278/mo Mochi Health, flat all-in; under active Lilly litigation | Weekly self-injection | Limited; FDA enforcement and Lilly litigation create supply risk |
Source: each program's own published pricing page + NovoCare and LillyDirect cash programs, verified against the GLP Chart Price Index, checked every Monday.
The cost picture, format by format
Compounded injectable semaglutide: cheapest cash path
The cheapest all-in monthly price for a semaglutide-based program in the US is Mochi Health at $178/month, flat across every dose tier. That flat pricing is the only thing that makes compounded competitive across the full titration arc: most programs price by dose tier, so the starter dose is cheap and the maintenance dose is more expensive. The gap between compounded and branded at the maintenance dose runs $121-$221/month depending on the program.
The risk is not clinical equivalence. The active molecule in compounded semaglutide is the same as Wegovy. The risk is regulatory and supply. A 503A pharmacy compounding semaglutide operates outside the branded supply chain; an FDA enforcement action or court order can halt supply quickly. That happened with compounded tirzepatide pharmacies in 2025.
Branded injectable Wegovy: the established cash path
The branded injectable Wegovy costs $349-$399/month through NovoCare at a maintenance dose, after the intro offer expired June 30, 2026. The injection comes in pre-filled pens at 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg, titrating over 16 weeks. For patients with insurance covering Wegovy, the injection is the dominant path because coverage is keyed to the branded injection NDA. The pill may or may not be covered under the same benefit, depending on how the insurer coded it.
Several telehealth programs dispense branded Wegovy injection alongside the pill: Hims, Ro, WeightWatchers Clinic, and Noom Med. The telehealth program membership fee adds $74-$149/month on top of the NovoCare medication price, so the all-in cash price at these programs runs $448-$548/month at maintenance.
Wegovy pill: the new cash math
At starter doses (1.5mg/4mg), the Wegovy pill costs $149/month through NovoCare. That price holds on the 1.5mg and 4mg tablets through August 31, 2026; after that the 4mg rises to $199/month. At maintenance doses (9mg/25mg), the pill costs $299/month.
The pill is available directly via NovoCare without a telehealth program membership, which shaves the membership cost out of the all-in number. Several programs also dispense it: Hims ($149 membership adds $149/mo), Ro ($44-$145/mo membership), WeightWatchers Clinic ($25-$74/mo membership). Run the math at your specific program; membership costs matter as much as the NovoCare pill price.
The pill requires a specific administration protocol: one tablet on an empty stomach with up to 4 oz of plain water, at least 30 minutes before eating, drinking anything other than water, or taking other medications. Missing that window reduces absorption. Patients who travel frequently, eat breakfast early, or take morning medications will find the daily injection-free routine trades one inconvenience for another.
Zepbound (tirzepatide): highest efficacy, injectable only
Tirzepatide remains injectable-only as of this writing. There is no approved oral tirzepatide for weight loss. Zepbound vials run $299-$449/month through LillyDirect depending on dose; the KwikPen version runs $449/month. Compounded tirzepatide starts at $278/month through programs like Mochi, but carries active FDA enforcement and Lilly litigation risk.
For patients who tolerate injectable semaglutide but plateau or underrespond, tirzepatide's dual GIP/GLP-1 agonist mechanism has shown stronger weight outcomes in the SURMOUNT-1 trial (~20% average weight loss at 15mg/week at 72 weeks). That efficacy advantage does not exist between injectable semaglutide and the oral Wegovy pill at the same doses.
Efficacy: what the trials actually show
A direct head-to-head trial between the Wegovy pill and the Wegovy injection has not been published. The comparison must be read across separate trials, in different populations, under different protocols, which limits what conclusions hold.
The STEP 1 trial of injectable semaglutide at 2.4mg/week found approximately 15% average body weight reduction at 68 weeks (published in the NEJM, 2021). The OASIS 1 trial of oral semaglutide at 50mg/week found approximately 15% average body weight reduction at 68 weeks (NEJM, 2023). Both used similar populations of adults with obesity or overweight with a weight-related comorbidity.
The commercial Wegovy pill doses top out at 25mg, not 50mg. Published efficacy data for the 25mg dose is still emerging. The FDA approved the pill based on the full dose range including 50mg; patients on the 25mg maintenance dose may see outcomes below the OASIS 1 headline. That is not a knock on the product; it reflects what the current evidence actually supports.
What is not in question: both formats use the same active molecule and the same mechanism of action. The question is absorption efficiency. Injectable semaglutide delivers dose reliably under the skin. Oral semaglutide absorption is pH-dependent and averages about 1% of the dose absorbed, which is why the pill doses run 20-30x higher than injectable equivalents to achieve similar blood levels.
Which format fits which patient
Injectable semaglutide (compounded or branded) fits the patient who is tolerating injections, already getting results, and does not want to change what is working. Switching for cost makes sense if the injection path costs more than $299/month all-in and the needle is a persistent friction point.
The Wegovy pill fits the cash-pay patient who wants a branded, FDA-approved product at a lower price than the injection, and who can commit to the daily empty-stomach protocol. It does not fit the patient who takes morning medications, eats breakfast first, or frequently travels with variable schedules.
Tirzepatide (Zepbound or compounded) is the format for the patient who underresponded to semaglutide and wants a different mechanism. No oral tirzepatide is available; the injectable format is the only option. For patients who responded well to semaglutide, switching to tirzepatide for the pill-versus-shot reason is not supported by evidence.
Compounded semaglutide is the cash-pay format for the cost-limited patient who accepts the regulatory tradeoff and wants the same weekly injection schedule at $120-$220 less per month. It belongs in the decision: not FDA-approved as a finished product, supply is tied to pharmacy compliance, and the market is under active enforcement pressure.
Price watch: what changes soon
Two specific dates matter for the cash pricing on the Wegovy pill:
- The 4mg Wegovy pill rises from $149 to $199 after August 31, 2026. If you are titrating on the starter dose, the window to lock in $149 pricing is limited.
- The NovoCare Wegovy injection intro offer ($199/month) ended June 30, 2026. The standard cash price reverted to $349-$399/month. Patients who started on the intro may see a significant bill change.
We track these prices every Monday. The GLP Chart Price Index shows the current all-in monthly cost across every US GLP-1 telehealth program, including programs that dispense the Wegovy pill.
Where to get the Wegovy pill
As of June 15, the following US telehealth programs dispense the oral Wegovy pill for weight management:
- Hims ($149/mo membership + NovoCare pill price; $448/mo all-in at maintenance, membership $39 first month)
- Ro Body ($44-$145/mo membership + NovoCare pill price; $373-$444/mo all-in at maintenance with annual vs. month-to-month membership)
- WeightWatchers Clinic ($25-$74/mo membership + NovoCare pill price; from ~$323/mo all-in at maintenance on the 12-month plan)
- Noom Med (via branded telehealth tier, $99/mo + medication separate)
- Knownwell (care via insurance-billed primary-care visit; NovoCare pill pricing applies; visits may be covered separately by insurance)
- NovoCare Direct (no telehealth membership; $149/mo starter, $299/mo maintenance, prescription required)
The list is expanding as programs update their formularies. Check the GLP Chart homepage for current availability flags.
Frequently asked questions
Is there an FDA-approved GLP-1 pill for weight loss?
Yes. Novo Nordisk's oral semaglutide tablet for weight loss, branded the Wegovy pill, received FDA approval in 2026. It is a different product from Rybelsus (oral semaglutide for type 2 diabetes, approved 2019) and is not the same as compounded oral semaglutide troches. The Wegovy pill comes in 1.5mg, 4mg, 9mg and 25mg doses. At maintenance doses (9mg/25mg) it costs $299/month through NovoCare. Several US telehealth programs including Hims, Ro, and WeightWatchers Clinic now dispense it alongside injectable Wegovy.
Is the Wegovy pill the same as Rybelsus?
No. Both contain semaglutide and both are oral tablets, but they are distinct FDA-approved products with different indications, dose ranges, and pricing. Rybelsus (approved 2019) is indicated for type 2 diabetes management at 3mg, 7mg, and 14mg doses; it costs roughly $998/month cash without insurance and is typically covered only with a T2D diagnosis. The Wegovy pill (approved 2026) is indicated specifically for chronic weight management at 1.5mg, 4mg, 9mg, and 25mg doses, with a NovoCare cash price of $149/month at starter doses and $299/month at maintenance doses.
Is the Wegovy pill cheaper than the Wegovy injection?
At maintenance doses, yes, the Wegovy pill runs cheaper than the injection through NovoCare. The pill is $299/month at maintenance doses (9mg/25mg). The Wegovy injection runs $349-$399/month cash after the NovoCare intro offer ends. The pill's starter-dose price of $149/month (1.5mg/4mg) is significantly cheaper than the injection's $199/month NovoCare intro. Note: the 4mg pill price of $149 is valid through August 31, 2026, then rises to $199.
How does compounded semaglutide compare to the Wegovy pill on cost?
Compounded injectable semaglutide from a telehealth program starts at $178/month all-in (Mochi Health, flat at every dose). The Wegovy pill costs $299/month at maintenance doses through NovoCare. So compounded injectable semaglutide is about $121/month cheaper than the oral Wegovy pill at maintenance, even though compounded is not FDA-approved as a finished drug product and carries different regulatory and supply risks.
Is the Wegovy pill as effective as the injection?
Clinical trial data shows the 50mg oral semaglutide dose (the OASIS 1 trial) achieved roughly 15% average weight loss, compared to approximately 15% for the injectable 2.4mg/week dose in the STEP 1 trial. These are different trials in different populations, so they cannot be directly compared head-to-head. The Wegovy pill launched at lower doses (up to 25mg); direct head-to-head efficacy data between the pill and the injection at equivalent dose periods is not yet published. Both carry the same molecule; absorption mechanics differ because the pill must be taken on an empty stomach with a small amount of water.
Who should consider the Wegovy pill over injectable Wegovy?
Patients who prefer not to self-inject and who are paying cash are the natural fit. The pill is also useful for patients who have a specific needle aversion. It is not a fit for patients with active inflammatory bowel disease or severe gastroparesis, since the absorption depends on gastric pH. Patients with good insurance coverage for the branded injectable may find the coverage structure differs for the pill product; eligibility requires verification with the insurer.
Is compounded oral semaglutide (troche) the same as the Wegovy pill?
No. The Wegovy pill is a Novo Nordisk FDA-approved product. Compounded oral semaglutide, sold as troches or sublingual formulations by some 503A pharmacies and telehealth programs, is not FDA-approved and has no peer-reviewed bioavailability data supporting equivalence to injectable semaglutide. Clinical evidence for the troche format is limited. They are priced differently and carry distinct regulatory status. This guide covers the FDA-approved Wegovy pill only; compounded oral troches are a separate product category.
See the live price of every GLP-1 program →
Read our compounded vs. branded cost study →
Compare GLP-1 drugs head to head (semaglutide vs tirzepatide, Wegovy vs Zepbound) →
Wegovy drug profile: dosing, efficacy, and prescribing criteria →
